Exploring the Pathogenesis of Lung Cancer from Xuanfu and Its Corresponding Syndrome Differentiation and Treatment Based on YE Tianshi's"Acrid"Theory
10.16466/j.issn1005-5509.2023.12.005
- VernacularTitle:从玄府探肺癌之病机及叶天士"辛味"理论在其辨治中的意义
- Author:
Weiling WANG
1
;
Yongjun ZHANG
;
Linmao YE
Author Information
1. 浙江中医药大学基础医学院 杭州31005
- Keywords:
Xuanfu;
lung cancer;
YE Tianshi;
"acrid"theory;
acrid drugs;
acridity tonifies deficiency;
acridity promotes stagnation
- From:
Journal of Zhejiang Chinese Medical University
2023;47(12):1406-1412
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To explore the pathogenesis of lung cancer from the perspective of Xuanfu,and to analyze the theoretical basis and clinical significance of YE Tianshi's acrid theory in the treatment of lung cancer.[Methods]According to the theory of Xuanfu,this paper discussed its influence on the occurrence,development and metastasis of lung cancer from three aspects:the loss of opening and closing of Xuanfu,the loss of"Xuanfu-collaterals"and the loss of"Xuanfu Qi-liquid".By reading YE Tianshi's A Guide to Clinical Practice with Medical Records,YE Tianshi's"acrid"theory and its differentiation and treatment experiences for cancer were summarized,and demonstrated it with a medical record.[Results]Xuanfu opening and closing loss,collaterals loss,Qi and liquid loss,the body's healthy Qi deficiency,Qi stagnation,blood stasis,phlegm and toxin interaction,led to the occurrence and development of lung cancer;YE Tianshi was good at using acrid drugs in the treatment of cancer,and advocated that acrid drugs could dispel wind,move Qi,dissolve phlegm,break concretions and tonify deficiency.In the elderly patients mentioned in the medical records,lung cancer recurred due to deficiency of Qi and stagnation of Xuanfu,phlegm and blood stasis.Therefore,the treatment of acridity was given,and lung cancer was alleviated.[Conclusion]YE Tianshi's"acrid"theory is suitable for different stages of lung cancer treatment by regulating the opening and closing of Xuanfu,which is worthy of clinical promotion.
